Related Experiment Video
Updated: May 3, 2026
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
Published on: March 1, 2024
Cross-talk between EphA2 and BRaf/CRaf is a key determinant of response to Dasatinib
Jie Huang1, Wei Hu, Justin Bottsford-Miller
1Authors' Affiliations: Departments of Gynecologic Oncology and Reproductive Medicine, Hematology and Oncology, Biostatistics, Cancer Biology, and Pathology, and The Center for RNA Interference and Non-Coding RNAs; The University of Texas MD Anderson Cancer Center, Houston, Texas.
Purpose:
EphA2 is an attractive therapeutic target because of its diverse roles in cancer growth and progression. Dasatinib is a multikinase inhibitor that targets EphA2 and other kinases. However, reliable predictive markers and a better understanding of the mechanisms of response to this agent are needed.
Experimental Design:
The effects of dasatinib on human uterine cancer cell lines were examined using a series of in vitro experiments, including MTT, Western blot analysis, and plasmid transfection. In vivo, an orthotopic mouse model of uterine cancer was utilized to identify the biologic effects of dasatinib. Molecular markers for response prediction and the mechanisms relevant to response to dasatinib were identified by using reverse phase protein array (RPPA), immunoprecipitation, and double immunofluorescence staining.
Results:
We show that high levels of CAV-1, EphA2 phosphorylation at S897, and the status of PTEN are key determinants of dasatinib response in uterine carcinoma. A set of markers essential for dasatinib response was also identified and includes CRaf, pCRaf(S338), pMAPK(T202/Y204) (mitogen-activated protein kinase [MAPK] pathway), pS6(S240/244), p70S6k(T389) (mTOR pathway), and pAKT(S473). A novel mechanism for response was discovered whereby high expression level of CAV-1 at the plasma membrane disrupts the BRaf/CRaf heterodimer and thus inhibits the activation of MAPK pathway during dasatinib treatment.
Conclusions:
Our in vitro and in vivo results provide a new understanding of EphA2 targeting by dasatinib and identify key predictors of therapeutic response. These findings have implications for ongoing dasatinib-based clinical trials.
Insights
This study identifies key markers like CAV-1 and EphA2 phosphorylation that predict response to dasatinib in uterine cancer. A novel mechanism involving CAV-1 disrupting the MAPK pathway was discovered, aiding clinical trial development.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- EphA2 plays a critical role in cancer progression, making it a significant therapeutic target.
- Dasatinib, a multikinase inhibitor, targets EphA2 but requires predictive markers for effective use.
- Understanding dasatinib's response mechanisms is crucial for optimizing cancer therapy.
Purpose of the Study:
- To identify reliable predictive markers for dasatinib response in uterine cancer.
- To elucidate the molecular mechanisms underlying response to dasatinib treatment.
- To investigate the therapeutic potential of targeting EphA2 in uterine carcinoma.
Main Methods:
- In vitro studies using human uterine cancer cell lines (MTT, Western blot, transfection).
- In vivo studies utilizing an orthotopic mouse model of uterine cancer.
- Molecular marker identification via reverse phase protein array (RPPA), immunoprecipitation, and immunofluorescence staining.
Main Results:
- High CAV-1 levels, EphA2 phosphorylation at S897, and PTEN status predict dasatinib response in uterine carcinoma.
- Identified key response markers including CRaf, MAPK pathway components (pCRaf, pMAPK), mTOR pathway components (pS6, p70S6k), and pAKT.
- Discovered a novel mechanism where high plasma membrane CAV-1 inhibits MAPK pathway activation by disrupting BRaf/CRaf heterodimers.
Conclusions:
- In vitro and in vivo findings offer new insights into EphA2 targeting by dasatinib.
- Key predictors of therapeutic response to dasatinib have been identified.
- These results have significant implications for ongoing dasatinib-based clinical trials.
Related Concept Videos
01:07MAPK Signaling Cascades
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:38Mitogens and the Cell Cycle
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...